New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
September 15, 2016 – Teva announced the launch of an authorized generic version of Merck’s Cubicin (daptomycin) 500 mg per vial injection.
Download PDF
Return to publications
